Bruker Corporation to Participate in the 2021 Jefferies London Healthcare Conference

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2021 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will participate in an analyst-moderated question and answer session on behalf of the Company on Tuesday, November 16, 2021 at 12:20 PM GMT. A live audio webcast... Read more

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio Extends capabilities in column performance for biopharma and proteomics researchers PHILADELPHIA, Nov. 1, 2021 /PRNewswire/ — ASMS 2021 — Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography columns. The... Read more

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

SANTA CLARA, Calif., October 21, 2021  Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and... Read more

Xylem Expands Partnership with Imagine H2O to Support Water Innovation Entrepreneurs

Global Partnership Scales Imagine H2O’s Work with Entrepreneurial Water Solutions RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 21, 2021– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s greatest water challenges has announced an expanded commitment to Imagine H2O, the leading water innovation accelerator and ecosystem for water entrepreneurs. As a global... Read more

PerkinElmer Participates in NIST Program to Advance Cannabis and Hemp Testing Standardization

Company’s Work with Federal organization focused on heavy metals and cannabinoid analysis aimed at helping labs and producers meet key regulations more effectively and efficiently October 19, 2021 WHAT : PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its participation in the National Institute of Standards and Technology’s (NIST)... Read more

Clear Labs Automated NGS Technology Platform (Clear Safety™) Approved by USDA’s National Poultry Improvement Plan for Salmonella Detection

Leader in Next-Generation Sequencing Workflow Automation Gains Agency Accreditation for Animal Health Testing SAN CARLOS, CALIF. (PRWEB) OCTOBER 14, 2021 Today, Clear Labs, a leader in providing fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, is announcing that Clear Safety Salmonella has been approved by the National Poultry Improvement Plan (NPIP) for interim use in the detection of... Read more

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif., October 13, 2021  Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.... Read more

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) 29% reduction in 48-week confirmed disability progression in primary progressive MS (PPMS) after 8 years vs. initiation after double-blind period in Phase III OLE New 8-year safety... Read more